Company news
Denali Therapeutics Inc. news in 2024
Denali Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
December 4, 2024
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 5, 2024
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
September 2, 2024
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following In...
August 13, 2024
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
July 31, 2024
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV: SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
June 2, 2024
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 6, 2024
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
April 30, 2024
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
February 26, 2024
Denali Therapeutics Announces $500 million Private Placement Equity Financing
February 26, 2024
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
February 6, 2024
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
January 31, 2024
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 7, 2024